100 Publikovaných vedeckých štúdií

TruAge Scanner Technology Key Publications

• Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score

for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Lutgers H. et al, Diabetologia, 2009;

52(5): 789-797

• Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type 2 diabetes

mellitus-a multi-centre study. Noordzij M.J. et al. Diabet Med. 2012 Dec;29(12):1556-61.

• Skin Autofluorescence and the Association with Renal and Cardiovascular Risk Factors in Chronic Kidney

Disease Stage 3. McIntyre N. et al. Clin J Am Soc Nephrol. 2011 Sep 1. Epub

• Skin-Autofluorescence Is an Independent Predictor of Graft Loss in Renal Transplant Recipients. Hartog J. et al.

Transplantation, Volume 87, Number 7, April 15, 2009

• Simple non-invasive assessment of advanced glycation endproducts accumulation. Meerwaldt R et al,

Diabetologia, 2004; 47:1324-1330

Diabetes

1. Skin autofluorescence is associated with past glycaemic control and complications in type 1 diabetes mellitus.

Genevieve M. et al. Diabetes Metab. 2013 May 2. [Epub ahead of print]

2. Advanced Glycation End Products Assessed by Skin Autofluorescence-A New Marker of Diabetic Foot Ulceration.

Vouillarmet J. et al. Diabetes Technol Ther. 2013 Apr 30. [Epub ahead of print]

3. Study design of DIACORE (DIAbetes COhoRtE) - a cohort study of patients with diabetes mellitus type 2. Dörhöfer L,

BMC Med Genet. 2013 Feb 14;14:25.

4. Verification of Skin Autofluorescence Values by Mass Spectrometry in Adolescents with Type 1 Diabetes: Brief Report.

Mácsai E. et al.Diabetes Technol Ther. 2013 Jan 23.

5. Advanced glycation end products in infant formulas do not contribute to insulin resistance associated with their

consumption. Klenovics KS. et al.PLoS One. 2013;8(1):e53056.

6. Advanced Glycation End Products, Measured as Skin Autofluorescence, During Normal Pregnancy and Pregnancy

Complicated by Diabetes Mellitus. de Ranitz-Greven WL. et al. Diabetes Technol Ther. 2012 Oct 31. (Epub)

7. Skin autofluorescence measurement in diabetological and nephrological clinical practice. Mácsai E. et al. Orv Hetil.

2012 Oct 21;153(42):1651-7.

8. Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type 2 diabetes mellitus-a

multi-centre study. Noordzij M.J. et al. Diabet Med. 2012 Aug 31. doi: 10.1111/dme.12005.

9. Advanced glycation end products measured by skin autofluorescence in a population with central obesity. den

Engelsen C. et al. Dermatoendocrinol. 2012 Jan 1;4(1):33-8.

10. Elevated skin autofluorescence is strongly associated with foot ulcers in patients with diabetes: a cross-sectional,

observational study of Chinese subjects. Hu H. et al. J Zhejiang Univ Sci B. 2012 May;13(5):372-7.

11. Advanced Glycation Endproducts and Diabetic Cardiovascular Disease. Prasad A. et al. Cardiol Rev. 2012 Feb 6. Epub

12. Non-invasive measures of tissue autofluorescence are increased in Type 1 diabetes complications and correlate with

a non-invasive measure of vascular dysfunction. Januszewski A.S. et al. Diabet Med. 2011 Dec 28. doi: 10.1111/j.1464-

5491.2011.03562.x.

13. Skin autofluorescence is associated with severity of vascular complications in Japanese patients with Type 2

diabetes. Tanaka K. et al. Diabet Med. 2011 Sep 14. Epub

14. Skin autofluorescence is inversely related to HDL anti-oxidative capacity in type 2 diabetes mellitus. Mulder D. et al.

Atherosclerosis. 2011 May, Epub

15. Advanced Glycation End Products, Measured as Skin Autofluorescence, at Diagnosis in Gestational Diabetes Mellitus

Compared with Normal Pregnancy. de Ranitz-Greven WL et al. Diabetes Technol Ther. 2011 Aug 29. Epub

16. Increased accumulation of skin advanced glycation end products is associated with microvascular complications in

type 1 diabetes. Araszkiewicz A. et al. Diabetes Technol Ther. 2011 Aug;13(8):837-42.

17. Assessment of skin autofluorescence as a marker of advanced glycation end product accumulation in type 1

diabetes. Samborski P. et al. Pol Arch Med Wewn. 2011 Mar;121(3):67-72.

18. Advanced glycation end products, measured as skin autofluorescence and diabetes complications: a systematic

review. Bos D.C. et al. Diabetes Technol Ther. 2011 Jul;13(7):773-9.

19. Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in

diabetic heart failure patients. Willemsen S. et al. Eur J. Heart Fail 2010. doi:10.1093/eurjhf/hfq168

20. Skin autofluorescence and glycemic variability. Noordzij M. et al. Diabetes Technol Ther. 2010; 12(7): 581-585

21. Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with

nephropathy, but not retinopathy. Chabroux S. et al: Diabetes Metab, 2010 Apr;36(2):152-7.

22. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for

the estimation of cardiovascular prognosis in type 2 diabetes mellitus Lutgers H. et al: Diabetologia, 2009; 52(5): 789-797

23. Skin Autofluorescence: A tool to identify type 2 diabetic patients at risk for developing microvascular disease. Gerrits

E. et al. Diabetes Care. 2008; 31: 517-521

24. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes Meerwaldt R, et al. Diabetes Care 2007,

30: 107-112

25. Skin autofluorescence in type 2 diabetes: Beyond blood glucose Monami M. et al. Diabetes Research & Clinical

Practice July 2007. epub

26. Non-invasive AGE-measurements by skin autofluorescence in patients with Type 2 Diabetes Mellitus. Tool for riskassessment of diabetes complications? Lutgers H, et al. Diabetes Care. 2006 Dec;29(12):2654-9

27. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation

of diabetic neuropathy Meerwaldt R, et al. Diabetologia. 2005;48:1637-44.

28. The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to

reduce AGE accumulation. Smit AJ, Lutgers HL.Curr Med Chem. 2004 Oct;11(20):2767-84.

Cardiovascular disease

29. Skin autofluorescence as proxy of tissue AGE accumulation is dissociated from SCORE cardiovascular risk score, and

remains so after 3 years. Tiessen AH. et al. Clin Chem Lab Med. 2013 Apr 2:1-7.

30. Skin Autofluorescence as a Measure of Advanced Glycation End Product Deposition Is Elevated in Peripheral Artery

Disease. de Vos L.C. et al. Arterioscler Thromb Vasc Biol. 2012 Nov 8. (Epub)

31. Relationship between tissue glycation measured by autofluorescence and pulse wave velocity in young and elderly

non-diabetic populations. Watfa G. et al. Diabetes Metab. 2012 Jun 13.

32. Advanced glycation end product associated skin autofluorescence: A mirror of vascular function? Hofmann B. et al.

Exp Gerontol. 2012 May 12.

33. Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in

patients with chronic heart failure. Hartog J.W. et al. BENEFICIAL investigators. Eur J Heart Fail. 2011 Aug;13(8):899-908.

34. Skin autofluorescence is increased in patients with carotid artery stenosis and peripheral artery disease. Noordzij MJ.

Int J Cardiovasc Imaging. 2011 Feb. Epub

35. Carotid artery intima media thickness associates with skin autofluoresence in non-diabetic subjects without clinically

manifest cardiovascular disease. Lutgers H. et al. Eur J Clin Invest. 2010 ;40(9):812-7

36. Advanced glycation end-products, anti-hypertensive treatment and diastolic function in patients with hypertension

and diastolic dysfunction. Hartog J. et al; Eur. Journal of Heart Failure, 2010 Apr;12(4):397-403

37. Advanced glycation end products in patients with cerebral infarction. Ohnuki Y. Intern Med. 2009;48(8):587-91.

38. Advanced Glycation End Products and their receptor RAGE in systemic autoimmune diseases - an inflamation

propagating factor contributing to accelerated atherosclerosis. Nienhuis et al. Autoimmunity, 2009; 42(4): 302-304

39. Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of

major adverse cardiac events Mulder D. et al, Netherlands Heart Journal, Volume 17, Number 4, April 2009

40. Relation between food and drinking habits,and skin autofluorescence and intima media thickness in subjects at high

cardiovascular risk Jochemsen M. et al: Journal of Food and Nutrition Research Vol. 48, 2009, No. 1, pp. 51–58

41. Advanced Glycation Endproducts (AGE) in chronic heart failure Smit A. et al. Annals of New York Academy of Science

2008; 1126:225-30

42. Clinical relevance of Advanced Glycation Endproducts for vascular surgery Meerwaldt R. et al. Eur J Vasc Endovasc

Surg. 2008; 38,125-131

43. Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels

of neopterin and the soluble receptor for advanced glycation end products. Mulder DJ. et al. Atherosclerosis.

2007:197:217-223

44. Clinical and prognostic value of Advanced Glycation End-products (AGEs) in chronic heart failure. Hartog J. et al Eur J

Heart Failure 2007;9:1146-55

45. Skin Autofluorescence is an independent marker for Acute Myocardial Infarction Mulder DJ, et al. Circulation: 2005;

112:II-371.

Renal disease  

46. Advanced glycation end-products and skin autofluorescence in end-stage renal disease: a review. Arsov S. et al. Clin

Chem Lab Med. 2013 Apr 4:1-10.

47. Accumulation of tissue advanced glycation end products correlated with glucose exposure dose and associated with

cardiovascular morbidity in patients on peritoneal dialysis. Jiang J. et al. Atherosclerosis. 2012 Sep;224(1):187-94.

48. Skin autofluorescence as a marker of cardiovascular risk in children with chronic kidney disease. Makulska I. et al.

Pediatr Nephrol. 2012 Sep 15. (Epub)

49. Factors influencing skin autofluorescence of patients with peritoneal dialysis. Mácsai E. et al. Acta Physiol Hung. 2012

Jun;99(2):216-22.

50. Decreased serum carnitine is independently correlated with increased tissue accumulation levels of advanced

glycation end products in hemodialysis patients. Adachi T. et al. Nephrology (Carlton). 2012 Jul 13. doi: 10.1111/j.1440-

1797.2012.01642.x.

51. Skin Autofluorescence: A Pronounced Marker of Mortality in Hemodialysis Patients. Gerrits E. et al. Nephron Extra.

2012 Jan;2(1):184-191.

52. Advanced oxidation protein products and advanced glycation end products in children and adolescents with chronic

renal insufficiency. Sebeková K. J Ren Nutr. 2012 Jan;22(1):143-8.

53. Evaluation of advanced glycation end products accumulation, using skin autofluorescence, in CKD and dialysis

patients. Oleniuc M. et al. Int Urol Nephrol. 2011 Oct;44(5):1441-9.

54. Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage

3. McIntyre N.J. et al. Clin J Am Soc Nephrol. 2011 Oct;6(10):2356-63.

55. Tissue level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive protein

levels in haemodialysis patients. Nagano M. et al. Nephrology (Carlton). 2011 Mar;16(3):299-303

56. Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic

kidney disease. Smit AJ. et al. Curr Opin Nephrol Hypertens, 2010: 19(6):527-33.

57. Skin autofluorescence is associated with renal function and cardiovascular diseases in pre-dialysis chronic kidney

disease patients. Tanaka K. et al. Nephrol Dial Transplant. doi: 10.1093/ndt/gfq369

58. Advanced glycation end products, carotid atherosclerosis, and circulating endothelial progenitor cells in patients

with end-stage renal disease. Ueno H et al. Metabolism, 2010, doi: 10.1016/j.metabol.2010.04.001

59. Tissue-Advanced Glycation End Product Concentration in Dialysis Patients McIntyre et al; CJASN, 2010; 5(1): 51-55

60. Does hepatitis C increase the accumulation of advanced glycation end products in haemodialysis patients? Arsov S.

et al. Nephrol Dial Transplant 2009; 25(3): 885-891

61. Skin-Autofluorescence Is an Independent Predictor of Graft Loss in Renal Transplant Recipients Hartog J. et al,

Transplantation • Volume 87, Number 7, April 15, 2009

62. Advanced Glycation End Products in Renal Failure: An Overview Noordzij M. et al, Journal of Renal Care 2008

63. AGEs, autofluorescence and renal failure Gerrits E. et al. Nephrology Dialysis and Transplantation November 25, 2008

64. Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial

stiffness in patients with end-stage renal disease Ueno H. et al: Metabolism Clinical and Experimental 57 (2008) 1452–

1457

65. Skin Autofluorescence, a measure of tissue advanced glycation endproducts (AGEs), is related to the diastolic

function of dialysis patients Hartog J. et al. Journal of Cardiac Failure. 2008; 14(7): 596-602

66. Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced

glycation end-products in renal transplant recipients Hartog JWL, et al. Nephrol Dial Transpl 2006 Aug;21(8):2263-9

67. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation endproducts, predicts

mortality in hemodialysis patients Meerwaldt R, et al. J Am Soc Nephrol 2005;16:3687-93.

68. Skin autofluorescence, a noninvasive measure of advanced glycation end product accumulation, is a predictor of

mortality in hemodialysis patients Meerwaldt R, et al. Ann N Y Acad Sci 2005;1043:911.

69. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Hartog JW.

et al. Ann N Y Acad Sci. 2005 Jun;1043:299-307.

70. Advanced glycation endproducts in kidney transplant patients: a putative role in the development of chronic renal

transplant dysfunction Hartog J. et al. Am J Kidn Dis 2004; 43:966-975

All other diseases

71. Plasma AGEs and skin autofluorescence are increased in COPD. Gopal P. et al. Eur Respir J. 2013 May 3. [Epub ahead

of print]

72. Increased advanced glycation end-products (AGEs) assessed by skin autofluorescence in schizophrenia. Kouidrat Y. et

al. J Psychiatr Res. 2013 Apr 21.

73. Local differences in skin autofluorescence may not reflect similar differences in oxidative stress exposure. Hettema

M. et al. J Rheumatol. 2013 Feb;40(2):206.

74. Vascular Aspects of Fabry Disease in Relation to Clinical Manifestations and Elevations in Plasma

Globotriaosylsphingosine. Rombach S.M. et al. Hypertension. 2012 Aug 6. (Epub)

75. Advanced Glycation Endproducts are increased in RA patients with controlled disease. de Groot L. et al. Arthritis Res

Ther. 2011 Dec 14;13(6):R205.

76. Increased skin autofluorescence after colorectal operation reflects surgical stress and postoperative outcome. Pol

H.W. et al. Am J Surg. 2011 Nov;202(5):583-9.

77. Skin autofluorescence, as marker of accumulation of advanced glycation endproducts and of cumulative metabolic

stress, is not increased in patients with systemic sclerosis. Hettema M.E.. et al. Int J Rheumatol. 2011. Epub

78. Skin advanced glycation end-product accumulation is negatively associated with calcaneal osteo-sono assessment

index among non-diabetic adult Japanese men. Momma H. Osteoporos Int. 2011 Sep 8. Epub

79. Skin autofluorescence is high in patients with cirrhosis - further arguing for the implication of Advanced Glycation

End products. Maury E. et al. J Hepatol. 2011 May;54(5):1079-80.

80. Skin advanced glycation end product accumulation and muscle strength among adult men. Momma H. et al; Eur J

Appl Physiol. 2010 (Epub)

81. Skin Autofluorescence as Marker of Tissue Advanced Glycation End-Products Accumulation in Formerly Preeclamptic

Women. Coffeng S.M. et al. Hypertens Pregnancy; 2010, Epub

82. Accumulation of advanced glycation end (AGEs) products in intensive care patients: an observational, prospective

study. Greven W. et al. BMC Clinical Pathology; 2010: 10 (4)

83. Increased accumulation of advanced glycation endproducts in patients with Wegener’s granulomatosis. Leeuw de K

et al. Ann Rheum Dis. 2009; 69(3): 625-U191

84. Skin autofluorescence is increased in systemic lupus erythematosus but not reflected by plasma levels advanced

glycation endproducts Nienhuis H. et al: Rheumatology. 2008; 47(10): 1554-1558

85. Skin autofluorescence is increased in systemic lupus erythematosus but not reflected by plasma levels of advanced

glycation endproducts Nienhuis H. et al. Rheumatology; 2008; 47(10): 1554-1558

86. Advanced glycation end products and the absence of premature atherosclerosis in glycogen storage disease Ia den

Hollander NC. et al. J Inherit Metab Dis. 2007. epub ahead of print

87. Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus. de Leeuw K. et al.

Rheumatol 2007;45:1551-1556.

88. Skin autofluorescence, a marker of advanced glycation end products and oxidative stress, is increased in recently

preelamptic women Blaauw J. et al. Am J Obstet Gynecol. 2006 Sep;195(3):717-22.

89. Enhanced skin autofluorescence as a marker for oxidative stress in sepsis, a pilot study. Mulder DJ, et al. Eur Soc

Intensive Care Medicine 2004

(Technical) validation

90. Reference values for the Chinese population of skin autofluorescence as a marker of advanced glycation end

products accumulated in tissue. Yue X. et al. Diabet Med. 2011 Jul;28(7):818-23.

91. Dermal factors influencing measurement of skin autofluorescence. Noordzij M.J. et al. Diabetes Technol Ther. 2011

Feb;13(2):165-70

92. Skin color independent assessment of aging using skin autofluorescence Koetsier M. et al. Optics Express, 2010

;18(14):14416-29

93. Reference Values of Skin Autofluorescence. Koetsier M. et al. Diabetes Technology & Therapeutics 2010; 12(5):399-

403

94. Skin autofluorescence for the risk assessment of chronic complications in diabetes: a broad excitation range is

sufficient Koetsier M. et al: Optics Express. 2009; 17(2): 509-519

95. Skin autofluorescence increases postprandially in human subjects Stirban A. et al. Diabetes Technology &

Therapeutics 2008: 10:200-5

96. The Effect of Aggressive Versus Conventional Lipid-lowering Therapy on Markers of Inflammatory and Oxidative

Stress. Mulder DJ. et al. Cardiovasc Drugs Ther. 2007 Apr;21(2):91-7.

97. Skin Autofluorescence, a Novel Marker for Glycation and Oxidative Stress derived Advanced Glycation Endproducts.

An Overview of Current Clinical Studies, Evidence and Limitations Mulder DJ, et al. Diabetes Technology and Therapeutics

2006; 8.523-535.

98. Simple noninvasive measurement of skin autofluorescence Meerwaldt R, et al. Ann N Y Acad Sci. 2005;1043:290-298.

99. Instrumentation for the measurement of Autofluorescence in the human skin Graaff R et al. Proc. of SPIE Vol. 5692

(SPIE, Bellingham, WA, 2005). pp. 111-118.

100. Simple non-invasive assessment of advanced glycation endproducts accumulation Meerwaldt R et al. Diabetologia

2004; 47:1324-1330

Kontakt

TruAge Slovakia Košice, Poprad, Banská Bystrica, Bratislava, Žilina truage.slovakia@gmail.com